Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...

– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– ...

MADRID, Spain—A novel patch-pump capable of delivering subcutaneous furosemide over a 5-hour period results in similar bioavailability and efficacy as an intravenous infusion and is well tolerated by ...

GHENT, Belgium, 23 April 2014 - Ablynx [Euronext Brussels: ABLX] today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of the evaluation of ...

Merck has presented early clinical data on subcutaneous formulations of its blockbuster checkpoint inhibitor Keytruda. The data drop is an early step in an ongoing effort to reformulate Keytruda ahead ...

Right on the heels of an FDA approval for the closely watched Alzheimer's disease drug Leqembi in an intravenous dose, Eisai is touting "promising" findings that the company says support the case for ...

EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is ...

LEXINGTON, Mass., scPharmaceuticals, Inc. today announced positive results from its pharmacokinetic and pharmacodynamics phase 3 pivotal registration trial. The trial in patients with heart failure ...

BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer ® technology, today announced successful ...